MEDI4736 monotherapy + tremelimumab+MEDI4736
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Pancreatic Ductal Adenocarcinoma
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Trial Timeline
Nov 16, 2015 → Jun 15, 2017
NCT ID
NCT02558894About MEDI4736 monotherapy + tremelimumab+MEDI4736
MEDI4736 monotherapy + tremelimumab+MEDI4736 is a phase 2 stage product being developed by AstraZeneca for Metastatic Pancreatic Ductal Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02558894. Target conditions include Metastatic Pancreatic Ductal Adenocarcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02558894 | Phase 2 | Completed |
Competing Products
20 competing products in Metastatic Pancreatic Ductal Adenocarcinoma